Publications 2013 to Present

  1. Egan BM. Metformin lower blood pressure in obese and insulin resistant individuals without diabetes. Journal of the American Society of Hypertension. 2017 (Hypertension Highlight);in press.
  2. Egan BM, Kai B, Wagner CS, Fleming DO, Henderson JH, Chandler AH, Sinopoli A. Low blood pressure is associated with greater risk for cardiovascular events in treated adults with and without apparent treatment resistant hypertension. Journal of Clinical Hypertension. Mar 2017;( DOI: 10.1111/jch.12904).
  3. Egan BM. Editorial commentary. Physical activity and hypertension: Knowing is not enough; We must apply. Willing is not enough; We must do-von Goethe. Hypertension. Mar 2017;69:404–406.
  4. Egan BM. Does SPRINT support a change in blood pressure targets: The importance of two implicit assumptions and blood pressure measurement methods. Journal of the American Society of Hypertension. Jan 2017.
  5. Turan TN, Lynn MJ, Nizam A, Egan BM, Le N-A, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, Janis S, Lane B, Montgomery J, Chimowitz MI. Relationship between risk factor control and vascular events in the SAMMPRIS Trial. Neurology. Jan 2017;88:1–7.
  6. Egan BM, Li J, White K, Fleming DO, Connell K, Hernandez GT, Ferdinand KC, Sinopoli A. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals. Journal of the American Heart Association. Oct 2016; 5:e003558 (doi: 10.1161/JAHA.116.003558).
  7. Motta J, Lemos T, Consolim-Colombo F, Gusmão M, Egan BM, Lopes H. Abnormalities of anthropometric, hemodynamic and autonomic variables prior to the onset of clinical significant disease in offspring of hypertensive parents. Journal of Clinical Hypertension. Sep 2016; doi: 10.1111/jch.12800.
  8. Egan BM, Laken MA, Sutherland SE, Qanungo S, Fleming DO, Cook AG, Hester WH, Jones KW, Jebaily GC, Valainis GT, Way CF, Wright MB, Davis RA. Aldosterone antagonists or renin-guided therapy for treatment resistant hypertension: A comparative effectiveness pilot study in primary care. American Journal of Hypertension. Aug 2016;29:976–983.
  9. Egan BM, Li J, Wagner CS. Systolic blood pressure intervention trial (SPRINT) and target systolic blood pressure in future hypertension guidelines. Hypertension. Aug 2016;68:318–323.
  10. Egan BM, Kai B, Wagner CS, Henderson JH, Chandler AH, Sinopoli A. Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment resistant hypertension. Journal of Clinical Hypertension. Aug 2016;18:827–824.
  11. Egan BM, Li J, Fleming DO, White K, Connell K, Davis RA, Sinopoli A. Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community-Based Practice Registry. Journal of Clinical Hypertension. Jul 2016;(Nov 26. doi: 10.1111/jch.12727).
  12. Sutherland SE, Egan BM, Fleming DO, Helmrich GA, Davis RA, Rutledge V, Sinopoli A. Medicare Shared Saving Program second-year results: Predictors of success. GHS Proceedins. May 2016;1:22–27.
  13. Egan BM, Sutherland SE, Childers WF, Dahlheimer RM, Helmrich GA, Lapeyrolerie DA, Markle N, Murphy DW, Simmons L, Davis RA, Tilkemeier P, Sinopoli A. Comparative impact of implementing the 2013 or 2014 Cholesterol Guidelines on vascular events in a quality improvement network. Therapeutic Advances in Cardiovascular Disease. Apr 2016;10:56–66.
  14. Egan BM, White K. Weight loss pharmacotherapy: Brief summary of the clinical literature and comments on racial differences. Ethnicity and Disease. Nov 2015;25:511–514.
  15. Egan BM. Treatment resistant hypertension. Ethnicity and Disease. Nov 2015;25:495–498.
  16. Puckrein G, Egan BM, Howard G. Social and medical determinants of cardiometabolic health: The big picture. Ethnicity and Disease. Nov 2015;25:521–524.
  17. Roberts DR, Zhu X, Tabesh A, Duffy EW, Ramsey DA, Brown TR. Structural Brain Changes following Long-Term 6 Degree Head-Down Tilt Bed Rest as an Analog for Spaceflight. American Journal of Neuroradiology. Nov 2015;36(11):2048-54. doi: 10.3174/ajnr.A4406. Epub 2015 Jul 16.
  18. Egan BM. Treatment resistant hypertension. A pragmatic management approach. Hypertension Journal. Oct-Dec 2015;1(2):106–110.
  19. Lackland DT, Egan BM. Epidemiology awareness, prevalence, and control: Newest findings on hypertension in blacks. Oct 2015;ch 2: 21–33. In: Hypertension in African Americans. K. Ferdinand, Ed., Springer Science+Business Media New York 2015.
  20. Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després J-P, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM. The cardiometabolic health alliance: Working toward a new care model for the metabolic syndrome. Journal of the American College of Cardiology. Sep 2015;66:1050–1067.
  21. Egan BM, Stevens-Fabry S. The importance of masked hypertension in adults with prehypertension. Nature Reviews Cardiology|Reply. Jul 2015;12:497.
  22. Wilson DK, Van Horn ML, Siceloff ER, Alia KA, St. George SM, Lawman HG, Trumpeter NM, Coulon SM, Griffin S, Wandersman A, Egan BM, Colabianci N, Forthofer M, Gadson B. The Results of the “Positive Action for Today’s Health” (PATH) trial for increasing walking and physical activity in underserved African American communities. Annals of Behavioral Medicine. Jun 2015;49:398–410.
  23. Egan BM. Elijah Saunders: In Memoriam. Journal of Clinical Hypertension. Jun 2015:17:415–417.
  24. Egan BM, Stevens-Fabry S. Pre-hypertension: Prevalence, health risks, and management strategies. Nature Reviews Cardiology. May 2015;12:289–300.
  25. Carter Bl, Coffey CS, Ardery G, Uribe L, Ecklund D, James P, Egan BM, Vander Weg M, Chrischilles E, Vaughn T. A cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circulation Cardiovascular Quality Outcomes. May 2015(3):235-243.(doi:10.1161/circoutcomes.)
  26. Egan BM, Bland VJ, Brown AL, Ferdinand KC, Hernandez GT, Jamerson KA, Johnson WR, Kountz DS, Li J, Osei K, Reed JW, Saunders E. Hypertension in African Americans aged 60–79 years: Statement from the International Society of Hypertension in Blacks. Journal of Clinical Hypertension. Apr 2015;17:252–259.
  27. Nietert PJ, Shaftman SR, Silver RM, Wolf BJ, Egan BM, Hunt KJ, Smith EA. Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. Clinical Epidemiology. Feb 2015;7:161–168.
  28. Moran WP, Zhang J, Gebregziabher M, Brownfeld EL, Davis KS, Schreiner A, Egan BM, Greenberg RS, Rogers TR III, Marsden JE, Ball SJ, Mauldin PD. Chaos to complexity: Leveling the playing field for measuring value in primary care. Journal of Evaluation in Clinical Practice. Feb 2015;(DOI: 10.1111/jep.12298).
  29. Boan AD, Egan BM, Bachman DL, Adama RJ, Feng W, Jauch EC, Ovbiagele B, Lackland DT. Antihypertensive medication persistence one year post stroke hospitalization. Journal of Clinical Hypertension. Dec 2014;16:869–874.
  30. Lopes HF, Klein RL, Garvey WT, Goodfriend T, Egan BM. Influence of acute hyperlipidemia to adipocyte-derived hormones in lean normotensive and subjects with metabolic syndrome. Diabetology & Metabolic Syndrome. Dec 2014;6:132.
  31. Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States 1999–2012: Progress toward Healthy People 2020 goals. Circulation. Nov 2014;30:1692–1699.
  32. Egan BM. Editorial Commentary – Effectiveness of a tailored behavioral intervention to improve hypertension control. Hypertension. Nov 2014;65:273–275.
  33. Egan BM, Li J, Small J, Nietert PJ, Sinopoli A. The growing gap in hypertension control between insured and uninsured adults: NHANES 1988–2010. Hypertension. Sep 2014;64:997–1004.
  34. Hailpern SM, Egan BM, Lewis KD, Wagner C, Shattat GH, Al Qaoud DI, Shatat IF. Blood pressure, heart rate and CNS stimulant medication use in children with and without ADHD: Analysis of NHANES data. Frontiers in Pediatrics. Sep 2014;2:100. (doi: 10.3389/fped.2014.00100).
  35. Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: Current perspectives. Diabetes, Metabolic Syndrome and Obesity. Sep 2014;7:421–435.
  36. Ostrye J, Hailpern SM, Jones J, Egan BM, Chessman K, Shatat IF. The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child. Pediatric Nephrology. Aug 2014:29:1403–1409.
  37. Jones JB, Shatat IF, Egan BM, Paulo RC. Decreased heart rate variability is associated with increased transcranial Doppler velocities in children with sickle cell disease. Ethnicity & Disease. Aut 2014;24:451–455.
  38. Hudson SM, Hiott DB, Cole J, Davis RA, Egan BM, Laken MA. Increasing capacity for quality improvement in under-resourced primary care settings. Quality Management of Health Care. Jul-Sep 2014;23:155–162.
  39. Egan BM. Opportunities for multidisciplinary ASH clinical hypertension specialists in an era of population health and accountable care: ASH leadership message. Journal for the American Society of Hypertension. Jul 2014;8:451–456.
  40. Dart RA, Egan BM. Formation of community-based hypertension practice networks: Success, obstacles, and lessons learned. Journal of Clinical Hypertension. Jun 2014;16:393–397.
  41. Egan BM, Li J, Shatat IF, Fuller JM, Sinopoli A. Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation. May 2014;129:2052–2061.
  42. Egan BM, Li J, Wolfman TE, Sinopoli A. Diabetes and age-related demographic differences in risk factor control. NHANES 1988–2010. Journal of the American Society of Hypertension. May 2014;8:394–404.
  43. Egan BM, Zhao Y, Li J, Brezezinski WA, Todoran TM, Brook RD, Calhoun DA. Comment on optimal treatment for resistant hypertension: The missing data on pulse-wave velocity. Hypertension. Mar 2014;63:e17–18 [PMID 24491391]).
  44. Julius S, Egan BM, Kaciroti N, Nesbitt S, Chen A for TROPHY investigators. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension. Journal of Hypertension. Feb 2014;32:251–259.
  45. Bhagatwala J, Harris RA, Parikh SJ, Zhu H, Huang Y, Kotak I, Seigler N, Pierce GL, Egan BM, Dong Y. Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives. Journal of Clinical Hypertension. Jan 2014;16:47–53.
  46. Egan BM, Laken MA. Pre-hypertension: Rationale for pharmacotherapy. Current Hypertension Reports. Dec 2013;6:669–675.
  47. Gil JS, Drager LF, Guerra-Riccio BM, Mostarda C, Irigoyen MC, Costa-Hong V, Bortolotto LA, Egan BM, Lopes HF. The impact of metabolic syndrome on metabolic, proinflammatory and prothrombotic markers according to the presence of high blood pressure criterion. Clinics. Dec 2013;68:1495–1501.
  48. Egan BM. Commentary: Prediction of incident hypertension: Health implications of data mining in the 'Big Data' era. Journal of Hypertension. Nov 2013;31:2123–2124.
  49. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment resistant hypertension in a community-based practice network. Hypertension. Oct 2013; 62:691–697.
  50. Becton L, Egan BM, Hailpern S, Shatat I. Blood pressure reclassification in adolescents based on repeat clinic blood pressure measurements. Journal of Clinical Hypertension. Oct 2013;15:717–722.
  51. Egan BM. Editorial commentary. Collecrin, an X-linked, ACE2 homolog causes hypertension in a rat strain through gene-gene and gene-environment interaction: Relevance to human hypertension. Circulation. Sep 2013;128:1727–1728.
  52. Egan BM. Editorial Commentary: Plasma lipidomic profile signature of hypertension in Mexican-American families. Hypertension. Aug 2013;62:453–454.
  53. Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: A report from NHANES 1988–2010. Circulation. Jul 2013;128:29–41.
  54. Coulon SM, Wilson DK, Egan BM. Associations among environmental supports, physical activity, and blood pressure in underserved African American adults in the PATH Trial. Social Science & Medicine. Jun 2013;87:108–115.
  55. Carter BL, Coffey CS, Uribe L, James PA, Egan BM, Ardery G, Chrischilles EA, Ecklund D, Vander Weg M, Vaughn T. Collaboration Among Pharmacists and physicians To Improve Outcomes Now (CAPTION) trial investigators. Similar blood pressure values across racial and economic groups: Baseline data from a group randomized clinical trial. Journal of Clinincal Hypertension. Jun 2013;15:404–412.
  56. Elliott WJ, Egan BM, Giles TD, Bakris GL, White WB, Sansone TM. Rationale for establishing a mechanism to increase reimubursement to hypertension specialists. Jorunal of Clinical Hypertension. Jun 2013;15:397–03.
  57. Egan BM, Zhao Y. Clinical epidemiology of hypertension in the U.S. 1999–2010: Different definitions of prevalent hypertension impact the clinical epidemiology of hypertension and attainment of Healthy People goals. Journal of Clinical Hypertension. Mar 2013;15:154–161.
  58. Egan BM, Grassi G. Editorial Commentary. Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension. Journal of Hypertension. Feb 2013;31:259–260.
  59. Laken MA, Dawson R, Engelman O, Lovelace O, Way C, Egan BM. Comparative effectiveness research in the "real" world: Lessons learned in a study of treatment-resistant hypertension. Journal of the American Society of Hypertension. Jan-Feb 2013;7:95–101.

Accepted Publications

  1. Sarasua S, Li J, Hernandez G, Ferdinand KC, Egan BM. The 2013 Cholesterol Guideline and opportunities for improving health equity. J Clin Hypertension. 2016:(accepted for publication).

Up to Date Publications

  1. Egan BM. Treatment of hypertension in the elderly, particularly isolated systolic hypertension. Ed., John P. Forman, section eds., George L. Bakris, Normal M. Kaplan, Kenneth E. Schmader, updated 01/28/2013, 01/02/2014, 06/05/2015.
  2. Egan BM. Treatment of hypertension in blacks. Ed., John P. Forman, section eds., George L. Bakris, Normal M. Kaplan, updated 02/02/2013, 01/21/2014.
  3. Egan BM. Treatment of hypertension in blacks. January 13, 2016 (last update).
  4. Egan BM. Hypertensive complications in blacks. June 20, 2016 (last update).
  5. Egan BM. Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension. June 28, 2016 (last update).
  6. Egan BM. Initial evaluation of the hypertensive adult. August 29, 2016 (last update).
  7. Egan BM. The prevalence and control of hypertension. 2017.

Login / Request Access